US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeOnc Technologies Holdings

4.26

-0.5050-10.61%

Post-market: 4.260.00000.00%16:05 EDT

Volume:17.55K

Turnover:78.31K

Market Cap:80.96M

PE:-1.60

High:4.76

Open:4.76

Low:4.26

Close:4.76

Loading ...

Overview Company News Filings

NeOnc Technologies Holdings Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Propel Clinical Trials and Enhance Oncology Programs

Neonc Technologies Holdings Inc. Files Initial Statement of Beneficial Ownership for Chief Clinical Officer Yousha Neman-Ebrahim

NeOnc Technologies Files Prospectus for Resale of Shares

MT Newswires Live

NeOnc Technologies files to sell 10.02M shares of common stock for holders

Neonc Technologies : Lead Asset Neo100 Nearing Phase 2a Completion Ahead of Schedule

THOMSON REUTERS

Neonc Technologies : Usc Brain Tumor Authority to Accelerate Four Clinical Trials

THOMSON REUTERS

NeOnc Technologies Appoints Dr. Josh Neman as Chief Clinical Officer to Propel Oncology Trials

Neonc Technologies Holdings Inc. Announces Retirement of COO Patrick Walters Effective June 1, 2025

Amir F. Heshmatpour, President of Neonc Technologies Holdings Inc., Reports Acquisition of Common Shares

CFO Garnett Keithly Reports Acquisition of Common Shares in Neonc Technologies Holdings Inc

President Amir F. Heshmatpour Reports Acquisition of Common Shares in Neonc Technologies Holdings Inc

Top Premarket Gainers

MT Newswires Live

Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

NeOnc Technologies announces global patent portfolio totals 176

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Expects Full Enrollment in Phase 2a Trialfor NEO100-01 by September

MT Newswires Live

BRIEF-Neonc Technologies Holdings Expects Full Enrollment In Promising Phase 2A Trial Of Neo100-01 For Malignant Gliomas In September

Neonc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President

THOMSON REUTERS

Press Release: NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Phase 1 Trial Enrollment for NEO212 Brain Cancer Drug Nears Full Enrollment

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NTHI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NTHI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":4.255,"timestamp":1750449600000,"preClose":4.76,"halted":0,"volume":17554,"hourTrading":{"tag":"盘后","latestPrice":4.255,"preClose":4.255,"latestTime":"16:05 EDT","volume":1535,"amount":6531.425,"timestamp":1750449948762},"delay":0,"floatShares":8005350,"shares":19026776,"eps":-2.651554,"marketStatus":"Market Closed","change":-0.505,"latestTime":"06-20 16:00:00 EDT","open":4.76,"high":4.76,"low":4.255,"amount":78308.663627,"amplitude":0.106092,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.651554,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":4.76,"preHourTrading":{"tag":"盘前","latestPrice":4.99,"preClose":4.76,"latestTime":"04:05 EDT","volume":66,"amount":329.67,"timestamp":1750406713767},"postHourTrading":{"tag":"盘后","latestPrice":4.255,"preClose":4.255,"latestTime":"16:05 EDT","volume":1535,"amount":6531.425,"timestamp":1750449948762},"volumeRatio":0.7523637293388893},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","floatShares":8005350,"roa":"-189.56%","roe":"--","lyrEps":-0.686076,"volumeRatio":0.7523637293388893,"shares":19026776,"dividePrice":0,"high":4.76,"amplitude":0.106092,"preClose":4.76,"low":4.255,"week52Low":4.1101,"pbRate":"-8.41","psRate":"1012.11","week52High":25,"institutionHeld":0,"latestPrice":4.255,"eps":-2.651554,"divideRate":0,"volume":17554,"delay":0,"ttmEps":-2.651554,"open":4.76,"prevYearClose":25,"prevWeekClose":5.61,"prevMonthClose":7.24,"prevQuarterClose":13.36,"fiveDayClose":6.4,"twentyDayClose":7.18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTHI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2543454775","title":"NeOnc Technologies Holdings Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Propel Clinical Trials and Enhance Oncology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2543454775","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543454775?lang=en_us&edition=fundamental","pubTime":"2025-06-13 04:55","pubTimestamp":1749761705,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Propel Clinical Trials and Enhance Oncology Programs. NeOnc Technologies Holdings, Inc. has appointed Dr. Josh Neman as the new Chief Clinical Officer. Dr. Neman, previously at USC's Keck School of Medicine, will accelerate NeOnc's clinical trials, including the lead asset NEO100 nearing Phase 2a completion. His expertise in cancer neuroscience is expected to enhance the company's clinical strategy and translational oncology programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ope","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL4Q94Bk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2542355739","title":"Neonc Technologies Holdings Inc. Files Initial Statement of Beneficial Ownership for Chief Clinical Officer Yousha Neman-Ebrahim","url":"https://stock-news.laohu8.com/highlight/detail?id=2542355739","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542355739?lang=en_us&edition=fundamental","pubTime":"2025-06-10 07:35","pubTimestamp":1749512153,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings Inc. Files Initial Statement of Beneficial Ownership for Chief Clinical Officer Yousha Neman-Ebrahim. Neonc Technologies Holdings Inc. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing mentions Yousha Neman-Ebrahim as the beneficial owner, holding the position of Chief Clinical Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2025, and i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDLbn5tzT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2542348339","title":"NeOnc Technologies Files Prospectus for Resale of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2542348339","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542348339?lang=en_us&edition=fundamental","pubTime":"2025-06-10 00:22","pubTimestamp":1749486142,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  on Monday filed a preliminary prospectus for the sale of up to about 10 million shares by Mast Hill Fund, a selling stockholder.In October 2024, it struck a deal with Mast Hill pursuant to which it may issue, from time to time, up to $50 million of its stock to the fund under an equity purchase agreement.Shares of NeOnc were over 1% lower in recent trading.Price: 7.28, Change: -0.14, Percent Change: -1.89","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2542336457","title":"NeOnc Technologies files to sell 10.02M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2542336457","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542336457?lang=en_us&edition=fundamental","pubTime":"2025-06-09 23:45","pubTimestamp":1749483910,"startTime":"0","endTime":"0","summary":"11:44 EDT NeOnc Technologies (NTHI) files to sell 10.02M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neonc-technologies-files-to-sell-10-02m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neonc-technologies-files-to-sell-10-02m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2541850249","title":"Neonc Technologies : Lead Asset Neo100 Nearing Phase 2a Completion Ahead of Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2541850249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541850249?lang=en_us&edition=fundamental","pubTime":"2025-06-06 21:03","pubTimestamp":1749215023,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nFWN3S90UO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2541850246","title":"Neonc Technologies : Usc Brain Tumor Authority to Accelerate Four Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2541850246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541850246?lang=en_us&edition=fundamental","pubTime":"2025-06-06 21:03","pubTimestamp":1749215023,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nFWN3S90UO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2541850286","title":"NeOnc Technologies Appoints Dr. Josh Neman as Chief Clinical Officer to Propel Oncology Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2541850286","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541850286?lang=en_us&edition=fundamental","pubTime":"2025-06-06 21:00","pubTimestamp":1749214817,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. has appointed Dr. Josh Neman as Chief Clinical Officer. Dr. Neman, previously associated with the University of Southern California, will lead the company's clinical development strategy, focusing on accelerating clinical trials, particularly the lead asset NEO100. His role will also involve expanding research collaborations and integrating AI and quantum computing into the drug delivery platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on June 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDLPkC3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","NTHI","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4585","BK4007","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2540070736","title":"Neonc Technologies Holdings Inc. Announces Retirement of COO Patrick Walters Effective June 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540070736","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540070736?lang=en_us&edition=fundamental","pubTime":"2025-06-04 05:00","pubTimestamp":1748984457,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings Inc. announced that Patrick Walters will retire from his position as Chief Operating Officer. His retirement will take effect on June 1, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL36Nhy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2537016688","title":"Amir F. Heshmatpour, President of Neonc Technologies Holdings Inc., Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2537016688","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537016688?lang=en_us&edition=fundamental","pubTime":"2025-05-24 09:31","pubTimestamp":1748050307,"startTime":"0","endTime":"0","summary":"Amir F. Heshmatpour, President and Director of Neonc Technologies Holdings Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250524:nNDL3WX7t9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Amir F. Heshmatpour, President of Neonc Technologies Holdings Inc., Reports Acquisition of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2537768920","title":"CFO Garnett Keithly Reports Acquisition of Common Shares in Neonc Technologies Holdings Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2537768920","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537768920?lang=en_us&edition=fundamental","pubTime":"2025-05-23 05:56","pubTimestamp":1747950982,"startTime":"0","endTime":"0","summary":"Garnett Keithly, the CFO of Neonc Technologies Holdings Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDLbWYlg8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2536655543","title":"President Amir F. Heshmatpour Reports Acquisition of Common Shares in Neonc Technologies Holdings Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2536655543","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536655543?lang=en_us&edition=fundamental","pubTime":"2025-05-20 07:03","pubTimestamp":1747695796,"startTime":"0","endTime":"0","summary":"Amir F. Heshmatpour, President and Director of Neonc Technologies Holdings Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDLXSlZ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2532765340","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2532765340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532765340?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:39","pubTimestamp":1746099585,"startTime":"0","endTime":"0","summary":"NanoVibronix  shares soared 64% pre-bell Thursday, rebounding from Wednesday's slide.Health Catalyst  shares increased 56% after Wednesday's 2.9% loss.NeOnc Technologies Holdings  shares rose 49% following a muted session.MaxCyte  shares advanced 30% after a 2.4% drop on Wednesday.Viavi Solutions  stock was up 22% following a muted session.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0205193047.USD","LU0240877869.USD","NAOV","NTHI","HCAT","BK4167","BK4082","BK4020","LU0240878834.USD","MXCT","VIAV","BK4007","BK4121","LU0205194284.USD","BK4539"],"gpt_icon":0},{"id":"2529050530","title":"Why Vertiv Holdings Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2529050530","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529050530?lang=en_us&edition=fundamental","pubTime":"2025-04-23 19:01","pubTimestamp":1745406097,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44945232/why-vertiv-holdings-shares-are-trading-higher-by-17-here-are-20-stocks-moving-premarket","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGI","USAW.SI","BK4094","MRIN","TSYW.SI","LU1093756325.SGD","NG","NDRA","MNQmain","QID","PEGA","LU2506951792.HKD","BK4212","BK4147","BK4118","FRGE","BCTX","BTOG","PSQ","VRT","BK4139","NTHI","ENPH","TQQQ","SEDG","LU1548497426.USD","NVIW.SI","BK4519","GAIA","AGMH","BK4588","ETNB","SQQQ","JYD","IE00BN0W2T93.GBP","NQmain","BK4543","BK4112","LU0823414478.USD",".IXIC","LU2357305700.SGD","BK4082","AGRI","IE00BMPRXR70.SGD","SNOA","USJW.SI","QLD"],"gpt_icon":1},{"id":"2527415751","title":"NeOnc Technologies announces global patent portfolio totals 176","url":"https://stock-news.laohu8.com/highlight/detail?id=2527415751","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527415751?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:35","pubTimestamp":1744720548,"startTime":"0","endTime":"0","summary":"NeOnc Technologies (NTHI) announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company’s IP portfolio, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neonc-technologies-announces-global-patent-portfolio-totals-176?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neonc-technologies-announces-global-patent-portfolio-totals-176?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2527418493","title":"NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2527418493","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527418493?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:05","pubTimestamp":1744718700,"startTime":"0","endTime":"0","summary":"-- 176 Patents Issued and Outstanding Reinforces NeOnc’s Competitive Position -- CALABASAS, Calif., April  15, 2025  (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmace","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3061691/0/en/NeOnc-Technologies-Global-Patent-Portfolio-Covers-Core-Pipeline-Across-All-Major-Pharmaceutical-Markets.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2527194992","title":"NeOnc Technologies Expects Full Enrollment in Phase 2a Trialfor NEO100-01 by September","url":"https://stock-news.laohu8.com/highlight/detail?id=2527194992","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527194992?lang=en_us&edition=fundamental","pubTime":"2025-04-14 23:34","pubTimestamp":1744644866,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  said Monday it expects full enrollment in a phase 2a trial for its therapeutic candidate NEO100-01 by September, with just six patients remaining to reach the 25-patient target.The trial is evaluating NEO100, which is intended for the treatment of malignant gliomas, particularly IDH1 mutant Grade III and IV astrocytomas. The read-out for the trial's data is expected early next year, the company said.The drug candidate has been granted orphan drug and fast-track status by the US Food and Drug Administration, according to the company.Price: 8.64, Change: -0.27, Percent Change: -3.03","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2527608591","title":"BRIEF-Neonc Technologies Holdings Expects Full Enrollment In Promising Phase 2A Trial Of Neo100-01 For Malignant Gliomas In September","url":"https://stock-news.laohu8.com/highlight/detail?id=2527608591","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527608591?lang=en_us&edition=fundamental","pubTime":"2025-04-14 22:10","pubTimestamp":1744639839,"startTime":"0","endTime":"0","summary":"BRIEF-Neonc Technologies Holdings Expects Full EnrollmentIn Promising Phase 2A Trial Of Neo100-01 For Malignant GliomasIn SeptemberApril 14 (Reuters) - Neonc Technologies Holdings Inc NTHI.O:NEONC TEC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nTUA30XSJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2526563198","title":"Neonc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President","url":"https://stock-news.laohu8.com/highlight/detail?id=2526563198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526563198?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:05","pubTimestamp":1744286700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUABJRR2Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2526631975","title":"Press Release: NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President","url":"https://stock-news.laohu8.com/highlight/detail?id=2526631975","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526631975?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:05","pubTimestamp":1744286700,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President. CALABASAS, Calif., April 10, 2025  -- NeOnc Technologies Holdings, Inc. , a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system  cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company's strategic and clinical initiatives.\"Amir's appointment as President reflects our commitment to strong, visionary leadership as NeOnc advances its clinical programs,\" said Dr. Thomas Chen, CEO of NeOnc. \"His extensive experience in building and scaling companies, coupled with his deep understanding of capital markets and business development, will be instrumental as we move forward.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4135","BK4555","TM","BK4585","NTHI","BK4604","BK4099","CNS","03160","BK4588"],"gpt_icon":0},{"id":"2526082335","title":"NeOnc Technologies Phase 1 Trial Enrollment for NEO212 Brain Cancer Drug Nears Full Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526082335","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526082335?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:39","pubTimestamp":1744144774,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  said Tuesday that its phase 1 trial of NEO212 for the treatment of brain cancer is nearing full enrollment.The final group is expected to complete the study's dosing protocol, the company said, adding that the NEO212 trial protocol has five escalating groups with three patients per group.NEO212 is a combination of temozolomide, which is the current standard-of-care chemotherapy for malignant gliomas, and perillyl alcohol, NeOnc said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NTHI"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTHI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTHI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NTHI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NTHI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NTHI","date":"2025-06-20","current":-1.928548,"percent":1,"low":-26.074295,"twenty":-14.191979,"median":-7.853798,"eighty":-2.929004,"high":-1.928548,"avg":-8.214755,"sd":6.099164,"marketCap":90567453},"quantilePoints":[{"date":"2024-03-28","current":-18.899455,"twenty":-18.899455,"median":-18.899455,"eighty":-18.899455,"marketCap":282000000},{"date":"2025-03-28","current":-18.905834,"twenty":-19.009816,"median":-18.905834,"eighty":-18.902007,"marketCap":224950380},{"date":"2025-04-04","current":-15.093157,"twenty":-20.260752,"median":-18.902645,"eighty":-16.151884,"marketCap":179585386},{"date":"2025-04-11","current":-14.179375,"twenty":-19.504518,"median":-17.739974,"eighty":-15.124667,"marketCap":168712785},{"date":"2025-04-17","current":-11.028403,"twenty":-19.044476,"median":-15.392499,"eighty":-12.855967,"marketCap":131221055},{"date":"2025-04-25","current":-9.437162,"twenty":-18.904558,"median":-14.667776,"eighty":-10.965384,"marketCap":112287731},{"date":"2025-05-02","current":-8.444606,"twenty":-18.667559,"median":-12.525115,"eighty":-9.437162,"marketCap":100477836},{"date":"2025-05-09","current":-10.398208,"twenty":-17.342951,"median":-11.028403,"eighty":-9.33318,"marketCap":123722709},{"date":"2025-05-16","current":-2.933338,"twenty":-15.682389,"median":-10.398208,"eighty":-8.444606,"marketCap":137753858},{"date":"2025-05-23","current":-2.969802,"twenty":-15.348385,"median":-9.44504,"eighty":-3.015179,"marketCap":139466268},{"date":"2025-05-30","current":-2.99006,"twenty":-15.171931,"median":-9.437162,"eighty":-2.969802,"marketCap":140417606},{"date":"2025-06-06","current":-3.034627,"twenty":-15.093157,"median":-9.311123,"eighty":-2.969802,"marketCap":142510552},{"date":"2025-06-13","current":-2.593006,"twenty":-14.242395,"median":-8.476116,"eighty":-2.937389,"marketCap":121771366},{"date":"2025-06-20","current":-1.928548,"twenty":-14.191979,"median":-7.853798,"eighty":-2.929004,"marketCap":90567453}],"updateTime":1750580854242}}}